The authors assessed the effects of switching from a conventional angiotensin II receptor blocker (ARB) to azilsartan on blood pressure (BP) and health-related quality of life (HR-QOL) in patients with uncontrolled hypertension. Key eligibility criteria were uncontrolled hypertension treated for !1 month with an ARB, excluding azilsartan, that did not reach the target BP. We recruited 147 patients (64 males and 83 females; mean ± standard deviation age 73 ± 15 years). Azilsartan reduced both systolic and diastolic BP significantly, from 151 ± 16/82 ± 12 to 134 ± 17/73 ± 12 mm Hg, 3 months after switching. Although scores on the comprehensive QOL scale, the EuroQoL 5 dimensions (EQ5D), and the simplified menopausal index (SMI) did not change, the Geriatric Depression Scale (GDS) score improved significantly, and there was a significant association between the change in the GDS score and systolic BP lowering (r = 0.2554, P = 0.030). The Pittsburgh sleep quality index (PSQI) improved significantly only in the female subgroup. Besides sufficient BP lowering activity, antihypertensive treatment with azilsartan may have a favorable impact on depression in geriatric patients with uncontrolled hypertension.
H ypertension (HT) is a major risk factor for cardiovascular disease (CVD), and there are gradual, continuous, and positive associations between the blood pressure (BP) level and the risk of CVD. [1] [2] [3] Although most trials have demonstrated that treatment of HT per se has reduced cardiovascular mortality and morbidity, [4] [5] [6] the optimal BP target for reduction of HT-related complications and adverse outcomes has been controversial for a long time. [7] [8] [9] [10] Recent studies showed that tight pharmacologic control of systolic BP to < 130 mm Hg achieved more favorable outcomes compared with standard treatment. 11, 12) Moreover, the SPLINT trial also revealed that more intensive treatment, to a systolic BP of less than 120 mm Hg, in patients without diabetes at increased risk for CVD significantly decreased rates of major cardiovascular events and death from any cause in comparison with standard treatment. 13) Thus, intensive treatment of HT is strongly required, especially in patients with a higher risk of CVD. 14) In the past half century in Japan, the number of patients receiving treatment for HT has increased continuously, with a resultant overall decrease in systolic BP; however, about 30% of male and 40% of female patients with HT still do not achieve their target BP. 15) Since HT often requires long-term treatment, it is important for patients to maintain good treatment adherence. Kim, et al. 16) reported that poor adherence to anti-hypertensive treatment was associated with higher mortality and a greater risk of hospitalization for CVD than good adherence (!80% cumulative medication adherence). Whether patients continue treatment may depend on, in part, their health-related quality of life (HR-QOL). Impaired HR-QOL was more often seen in patients with HT than in normotensive and borderline hypertensive patients. 17) In addition, previous studies have shown that improvements in HR-QOL are expected with treatment of HT. 18, 19) Since the mid-2000s, many randomized studies have evaluated the effect of cardiac rehabilitation (CR) on various types of CVD, such as chronic heart failure (CHF), coronary artery disease (CAD), and post-heart transplantation, from the aspect of improvement of HR-QOL in addition to clinical symptoms and outcomes. [20] [21] [22] [23] It is therefore necessary to evaluate the effect of anti-hypertensive treatment on HR-QOL in the current era, when some evidence supporting intensive treatment of HT has been demonstrated.
We therefore designed a clinical study to test the effect of an angiotensin II receptor blocker (ARB) on blood pressure and quality of life (APEQ Study). The aim of the study was to assess the effects of switching from a conventional ARB to azilsartan, which is known to provide more effective HT control within the ARB class, 24) on BP control and HR-QOL in patients with uncontrolled HT. This study may clarify the effect of sufficient treatment with azilsartan on HR-QOL in addition to an effect on uncontrolled HT, potentially leading to the validity of sufficient treatment of HT from the psychosocial and mental aspects.
Methods
The APEQ study was a non-randomized prospective single-arm multicenter open-label study registered in the University Hospital Medical Information Network (UMIN) Clinical Trials Registry system (UMIN ID: 000009469). Prior to study initiation, the study protocol was approved by the local institutional review boards and independent ethics committees at every site. The study was conducted in full compliance with the Declaration of Helsinki and was carried out according to the Ethical Guidelines for Clinical Research established by the Ministry of Health, Labour, and Welfare. The APEQ investigators are listed separately (Supplemental Text). Study participants and sample size: Among patients with HT who had been treated with monotherapy or a combination of an ARB (except for azilsartan) and other classes of anti-hypertensive agents for at least one month, eligible participants were those that did not achieve the target BP stated in the guideline (Details in Supplemental Table I) . 25) The sample size was initially estimated based on a previous report, in which decreases in BP of about 300 patients administered azilsartan were greater than those of about 300 patients administered candesartan. 26) Given the single-arm design of our study, the sample size was set at 200 patients. The investigators screened patients according to their medical records, were required to provide every participant with an adequate explanation of the trial plan, and were required to obtain written informed consent from every participant. Study design and treatment: All participants switched their ARB to azilsartan 20 or 40 mg once daily based on the dosage of their original ARB and continued receiving azilsartan for 3 months. The patients who received a standard dose of ARB switched to azilsartan 20 mg; in contrast, the patients who received a high dose of ARB switched to azilsartan 40 mg (Supplemental Figure 1) . All participants went to see their usual care physicians monthly to receive usual care and the study drug. It was also required that the participant's background treatment, including anti-hypertensive agents and drugs for other complications, was, in principle and if possible, unchanged during the trial interval.
Measurements and endpoints:
At study initiation, the participants' background information, including age, sex, body height, body weight, abdominal circumference (optional), complications, and smoking and drinking history, was collected. The primary endpoint was the change in office BP from baseline to 3 months after switching. The key secondary endpoints were the changes in HR-QOL scores, such as the EuroQoL 5 dimensions (EQ5D), the Pittsburgh sleep quality index (PSQI), the Geriatric Depression Scale (GDS), and the simplified menopausal index (SMI), and specific biomarkers, including small-dense low-density lipoprotein-cholesterol (sd LDL-C), malondialdehyde modified-LDL (MDA-LDL), high-sensitivity C-reactive protein (hs-CRP), remnant-like lipoprotein particles cholesterol (RLP-C), and free testosterone (FT, only in males), from baseline to 3 months after switching. Statistical analysis: All statistical analyses were performed on the full analysis set, which included all patients who received at least one dose of treatment during the study period, did not have any serious non-compliance with the study protocol, and had data collected after the commencement of treatment. For the baseline variables, summary statistics are shown as frequencies and proportions for categorical data and as the average and standard deviation (SD) for continuous variables. Each value of interest at baseline and 3 months after switching was independently compared with paired t-tests, and the change from baseline to 3 months after switching and 95% confidence interval were estimated based on the t-distribution. Changes in BP according to the number of class in antihypertensive agent at baseline were compared with unpaired t-tests. Correlations between variables were analyzed by Pearson's correlation coefficient. A P value < 0.05 was considered statistically significant. All statistical analyses were performed using SAS software version 9.3 (SAS Institute, Cary, NC, USA). (Table I) From February 2013 to June 2014, a total of 147 eligible patients (64 males, 83 females; mean ± SD age, 72.8 ± 15.3 years) were recruited into this study. Among them, 8 patients dropped out during the study due to 1 admission for angina pectoris, 1 death from pneumonia, 2 changing hospitals, 1 progression of lung cancer, 2 loss of contact, and 1 gastric distress after switching to azilsartan. The mean ± SD body mass index was 24.4 ± 5.2%, and the mean ± SD abdominal circumference was 87.4 ± 12.6 cm (n = 71). The prevalence of dyslipidemia and diabetes was 41.5% and 35.4%, respectively. The percentage of patients who received anti-hypertensive treatment only with ARB was 40.8% at baseline, and the others received two (39.5%), three (15.6%), four (3.4%), or five (0.7%) classes of anti-hypertensive agent, including their original ARB. At least, 71 patients (48.3%) received a calcium channel blocker in conjunction with an ARB at baseline, but no patient received an angiotensin converting enzyme (ACE) inhibitor. The original ARB administered was olmesartan in 31.3%, candesartan in 26.5%, telmisartan in 21.8%, valsartan in 13.6%, losartan in 4.1%, and irbesar-Fujiwara, ET AL Figure 1A ). The mean ± SD change in BPs 3 months after switching were -16.9 ± 20.1 mm Hg (systolic) and -8.9 ± 11.6 mm Hg (diastolic). The higher their baseline BPs were, the greater the amounts of reduction in BPs 3 months after switching were (Figure 1 B). However, this BP reduction was not associated with the number of class of anti-hypertensive agent administered at baseline (Supplemental Figure 2) .
Results

Patient baseline characteristics
Changes in HR-QOL scores 3 months after switching:
There was no significant difference in any of the HR-QOL scores at baseline between sex. The GDS score improved significantly (P = 0.013) in the total population of patients after 3 months, and this effect was strongly attributed to the female subgroup (Table II) . Although the PSQI did not change in the total population of patients, azilsartan improved it only in the female subgroup (P = 0.040), but not in the male subgroup. There were no significant changes in the SMI and the EQ5D, even in the female subgroup. The ΔGDS was weakly but significantly correlated with Δsystolic BP in the total population (r = 0.2554, P = 0.030, Figure 2A ) and in the female subgroup (r = 0.4307, P = 0.018), but not the ΔPSQI ( Figure 2B ). These results indicate that HR-QOL scores such as the GDS and PSQI, especially in the female subgroup, were significantly improved by switching the ARB to azilsartan, and there was a significant correlation between reduction in systolic BP and improvement in GDS score.
Impact of baseline HR-QOL:
We divided the patients, who had data of BP and each HR-QOL both at baseline and 3 months, into two subgroups according to the median value of each HR-QOL score at baseline. As a result, there were significant reductions in the GDS score (median = 3, n = 44; baseline, 5.84 ± 2.90 versus 3M, 4.36 ± 3.55, P < 0.001), PSQI (median = 5, n = 43; baseline, 8.63 ± 3.53 versus 3M, 7.60 ± 4.30, P = 0.011), and SMI (median = 16, n = 39, baseline 30.03 ± 13.18 versus 3M 24.49 ± 13.98, P = 0.001) in patients whose HR-QOL score at baseline was greater than or equal to each median value ( Figure 3 ). The EQ5D was also significantly improved in patients whose baseline EQ5D was less than or equal to the median value (median = 0.795, n = 36; baseline, 0.70 ± 0.08 versus 3M, 0.77 ± 0.16, P = 0.004) (Figure 3 ). There were significant decreases in either systolic or diastolic BP 3 months after switching in each subgroup (Supplemental Figure 3) . In contrast, there were no significant correlations between the improvements in each HR-QOL score and the degree of change in either systolic or diastolic BP (Supplemental Figure 4) . In addition, we found no significant changes on the GDS and PSQI in the patients with baseline scores less than each median value (Supplemental Figure 5) . In contrast, the SMI in patients with baseline scores less than median value and EQ5D in those with baseline scores more than median value were increased (SMI) and decreased (EQ5D) 3 months after switching. Taken together, switching ARB therapy to azilsartan improved several HR-QOL scores independently from the degree of BP lowering in patients whose HR-QOL at baseline were relatively low. Changes in laboratory tests including biomarkers 3 months after switching: There were no significant changes in the lipid and glycemic profiles, uric acid, and liver enzymes 3 months after switching. Serum creatinine increased significantly, but slightly, and potassium decreased significantly, but slightly, 3 months after switching (Table III) . Because azilsartan was switched from original ARB, not first-time ARB, this switching might less affect the potassium level. However, the exact reason for decrease in the potassium level was undetermined in the present study. Biomarkers, including sd LDL-C, MDA-LDL, hs-CRP, RLP-C, and FT (only in male) were unchanged 3 months after switching (Table IV) . Improvement in the GDS score in the total population was not associated with a change in such biomarkers (Supplemental Figure 6) In the female subgroup, there were also no significant correlations between changes in these biomarkers, except for FT and the degree of improvement on the GDS or PSQI (Supplemental Figure 7) . In addition, we also found no significant correlations between each ΔHR-QOL and Δbiomarker in the subgroup [patients with each HR-QOL score "(GDS, PSQI, SMI) or !(EQ5D) median values at baseline], except between ΔMDA-LDL and Δ EQ5D (Supplemental Figure 8) . Altogether, azilsartan reduced BP and improved HR-QOL scores independently from inflammatory or gonadal biomarkers evaluated in the study.
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Discussion
In the present study, switching from a conventional ARB to azilsartan improved the GDS score significantly in addition to lowering BP sufficiently. Further, improvements in several HR-QOL scores in subgroups, such as females or patients with lower HR-QOL at baseline, were demonstrated in addition to sufficient BP lowering. Importantly, no worsening of HR-QOL was documented during the study. As accumulating evidence suggests favorable effects of sufficient or intensive BP lowering treatment on pathophysiological aspects, including cardiovascular prognosis, [11] [12] [13] [14] our results may further support such a treatment strategy from the psychosocial standpoint, possibly leading to augmentation of adherence with treatment. Recent progress in medical technology and cardiovascular pharmaceuticals has highlighted that the improvement of functional and psychosocial HR-QOL beyond a good longitudinal prognosis is needed as an aim of medical treatment. The recent treatment guidelines for rehabilitation in patients with CVD also describe the importance of clinical evaluation focused on HR-QOL. 27 ) Depression is a major risk factor affecting HR-QOL, and it is bidirectionally associated with several CVDs including HT, CAD, CHF, and pulmonary HT. [28] [29] [30] [31] [32] [33] In patients with HT, it is reported that the prevalence of depression is 27%. 34) Accumulating evidence suggests that CR, such as exercise training for patients with CHF, can improve HR-QOL. 20, 35) Thus, early detection and appropriate intervention into depression would be greatly needed in addition to treatment for background CVDs. 36, 37) Relative to other CVD, such as CAD and CHF, the impact of HT on HR-QOL may be less, but it is reported that psychosocial factors contribute to the development of HT, and a higher level of BP induced more physical, emotional, and psychosocial impairments. 17, 38) Since it often takes long-term treatment to manage HT, maintenance of adherence to treatment is critical to avoid treatment dropout. Therefore, physicians must evaluate patients' HR-QOL comprehensively from various points of view and follow them up in clinical settings. 39) Some previous studies reported that the effect on HR-QOL differed somewhat among anti-hypertensive agents, and ACE inhibitors and ARBs have, in part, favorable effects. 18, 40, 41) It is reported that there was no sex difference in HT treatment-mediated effects, including cardiovascular outcomes and HR-QOL, 42) while the present study showed, in part, some differences between sex. Biological differences between sex, such as endocrinological and physical function, might presumably contribute to the present results; however, the definitive reasons are still unclear. There are several reports that demonstrate sex-related differences in response to some antidepressants, in which females re-AZILSARTAN ON BLOOD PRESSURE AND QUALITY OF LIFE Figure 2 . Correlations between ΔHR-QOL score and ΔBP. A: Correlations between ΔGDS and ΔBP of participants in the total study population who had both pre-switch and post-switch BP and GDS data. B: Correlations between each ΔGDS/ΔPSQI and ΔBP in participants in the female subgroup who had both pre-switch and post-switch BP and GDS or PSQI data. BP indicates blood pressure; GDS, geriatric depression scale; and PSQI, Pittsburgh sleep quality index.
spond better than males. 43) Su, et al. 44) reported that in the cross-sectional study, there was a clear association between scores on the GDS and PSQI only in the female subgroup. Thus, improvement of HR-QOL by switching to azilsartan might, in part, depend on sex and HR-QOL status at baseline.
Azilsartan is known to provide greater and more sustained binding to and blocking of the angiotensin type 1 receptor within the ARB class, potentially leading to a higher rate of well-controlled HT. 45) In the present study, switching from a conventional ARB to azilsartan also reduced both systolic and diastolic BP and improved some HR-QOL scores, especially in the geriatric depression. Given the multi-factorial characteristics of such mental conditions, it may be difficult to determine only one contributing factor. Regarding to BP lowering, because participants could easily realize their sufficient BP lowering effect in the present study, increased satisfaction to treatment might, in part, favorably affect their mental condition. Although the renin-angiotensin system is indeed distributed throughout systemic tissues including the brain, the ability of ARBs, including azilsartan, to cross the blood-brain barrier (BBB) is minimally limited and not fully conclusive. 46, 47) In previous studies regarding HT and dementia, ARBs and ACE inhibitors with a higher degree of BBB penetration could prevent the development of dementia; however, this preventative effect was not confirmed in randomized controlled trails. 48, 49) Thus, the precise mechanisms by which ARBs and ACE inhibitors affect psychiatric and cognitive functions are yet unclear.
In the current study, improvement in HR-QOL scores was dependent on sex and HR-QOL status at baseline. However, biomarkers did not change during the 3-month intervention and did not correlate with changes in HR-QOL scores. It is reported that hs-CRP is an independent risk factor for de novo major depressive disorder in women. 50) Thus, accumulated evidence demonstrates that inflammatory processes play an important role of the pathogenesis in major depressive disorder. 51) There may be at least two possible reasons why the inflammatory biomarkers did not change in contrast to improvement of the GDS score: pre-suppression of inflammation by the original ARB prior to azilsartan and a relatively small, but significant, range of changes in the GDS score under the AZILSARTAN ON BLOOD PRESSURE AND QUALITY OF LIFE subclinical level. Taken together, these results and speculations suggest that sufficient BP lowering by switching to azilsartan improved the GDS score independently of the inflammatory process. The present study has several limitations. First, this study was a non-randomized, single-arm study with a limited number of patients. Whether azilsartan specifically improved some HR-QOL scores cannot be determined. Therefore, we would need to evaluate whether sufficient BP lowering by other anti-hypertensive agents such as calcium channel antagonist, or increased doses of original ARBs also could improve HR-QOL in appropriate designs. Second, the mean values of the HR-QOL scores evaluated in this study were relatively low. Such levels may not be associated with clinical symptoms, but they may reflect a subclinical condition before the onset of a future mental disorder. Third, the mean age of the participants was high, 73 ± 15 years. It might be therefore inappropriate to analyze menopausal symptoms. Fourth, a minor proportion of participants had been taking mentalrelated agents, such as anti-anxiety or anti-depressant agents, and previous history of mental-related disorders might not be fully evaluated. This might be influenced the current findings. Finally, as this study demonstrated very short-term effect of sufficient treatment by switching from a conventional ARB to azilsartan, the longer-term effect on HR-QOL is yet to be determined.
In conclusion, sufficient anti-hypertensive treatment by switching from a conventional ARB to azilsartan may have a favorable impact on depression in patients with uncontrolled HT in addition to sufficient BP reduction. Importantly, there was at least no worsening of HR-QOL scores during the 3 months of treatment. These results may support the significance of sufficient BP lowering treatment on psychosocial aspects, potentially resulting in the achievement of well-controlled BP without treatment dropout.
